Efficacy and safety of neoadjuvant chemotherapy followed by radical surgery vs. radical surgery alone in locally advanced cervical cancer: A systematic review and meta-analysis

新辅助化疗联合根治性手术与单纯根治性手术治疗局部晚期宫颈癌的疗效和安全性:系统评价和荟萃分析

阅读:1

Abstract

Locally advanced cervical cancer (LACC) poses a significant therapeutic challenge, particularly in defining the optimal role of neoadjuvant chemotherapy (NACT) followed by radical surgery (RS) relative to surgery alone. Existing literature offers conflicting evidence on survival benefits, highlighting the need for further clarification. In the present study, the PubMed, EMBASE, Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews databases were systematically searched for studies comparing NACT plus RS vs. RS alone in patients with International Federation of Gynecology and Obstetrics stage IB2-IIB cervical cancer. Eligible trials reported at least one major outcome [overall survival (OS) or disease-free survival (DFS)]. Odds ratios (ORs) were calculated using a random-effects model. Sensitivity analyses, assessment of publication bias and quality evaluations were performed. Seven studies encompassing 2,231 patients were included. The pooled estimate for DFS did not differ significantly between groups (OR, 0.98; 95% CI, 0.62-1.56; P=0.941), despite some individual studies showing improvements. Subgroup meta-analysis of OS found a significant advantage favoring NACT plus RS (OR, 0.53; 95% CI, 0.32-0.87; P=0.012). However, when all OS data were combined, the observed benefit approached but did not achieve statistical significance (OR, 0.74; 95% CI, 0.53-1.04; P=0.078). Leave-one-out sensitivity analyses confirmed the robustness of findings for OS and the consistent null effect for DFS. Publication bias assessments were largely negative, indicating minimal risk of missing or selectively reported studies. The NACT group had lower postoperative complications and radiotherapy needs but higher hematological toxicity and surgical complexity. In conclusion, NACT followed by RS may confer a borderline or subgroup-specific survival advantage over RS alone for LACC. However, the overall benefit remains inconclusive for DFS. Clinicians should balance potential gains against treatment-associated risks when considering NACT in routine practice.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。